Myostatin is a negative regulator of muscle growth – a protein that stops muscle building and doesn’t let them get too big, as part of the natural regeneration process. In other words, if we can decrease myostatin in the body, could we increase muscle growth?
This approach has been pursued by several companies. With the recent termination of Pfizer’s anti-myostatin, Domagrozumab, families are wondering if myostatin is still a viable therapeutic target in Duchenne. Our recent webinar with Dr. Lee Sweeney reviewed existing myostatin data and discuss questions and considerations going forward.